{
    "cancelStatus": "0",
    "licStatus": "1",
    "cancelDate": null,
    "cancelReason": [],
    "otherCancelReason": "",
    "licid": "60001089",
    "licUnit": "1",
    "validDate": "2028-12-06 00:00:00.000",
    "issueDate": "2018-12-06 00:00:00.000",
    "oriIssueDate": "2018-12-06",
    "licKind": "04",
    "oldLicid": null,
    "certNo": "DHA06000108900",
    "prodNameC": "癌吉清凍晶注射劑440毫克",
    "prodNameE": "Ogivri 440 mg",
    "indicationsName": [
        "Ogivri應使用於下列HER2過度表現或HER2基因amplification之早期乳癌、轉移性乳癌病人，說明：\r\n1. 早期乳癌(EBC)\r\n(1) 經外科手術、化學療法(術前或術後)之輔助療法。\r\n(2) 以doxorubicin與cyclophosphamide治療，再合併paclitaxel或docetaxel之輔助療法。\r\n(3) 與docetaxel及carboplatin併用之輔助療法。\r\n(4) 術前與化學療法併用和術後之輔助療法使用於治療局部晚期(包括炎症)乳癌或腫瘤(直徑>2厘米)。\r\n2. 轉移性乳癌(MBC)\r\n(1) 單獨使用於曾接受過一次(含)以上化學療法之轉移性乳癌；除非病人不適合使用anthracycline或taxane，否則先前之化學治療應至少包括anthracycline或taxane。使用於荷爾蒙療法失敗之荷爾蒙受體陽性之病人，除非病人不適用荷爾蒙療法。\r\n(2) 與paclitaxel或docetaxel併用於未曾接受過化學療法之轉移性乳癌。\r\n(3) 與芳香環酶抑制劑併用於荷爾蒙受體陽性之轉移性乳癌\r\n3. 轉移性胃癌(mGC)\r\nOgivri合併capecitabine (或5-fluorouracil)及cisplatin適用於未曾接受過化學治療之HER2過度表現轉移性胃腺癌(或胃食道接合處腺癌)的治療。說明：\r\n(1) HER2過度表現之檢測方法須經衛生主管機關核准(用於胃癌之檢驗)，請參照相關檢測套組仿單中適應症，確效(validation)及效能(performance)之敘述。另請參照本仿單[臨床研究-轉移性胃癌]之敘述。\r\n(2) 樞紐試驗確認療效僅顯現於有較高HER2蛋白表現(IHC2+\/FISH+或IHC3+)之族群。HER2次族群分析結果顯示，HER2蛋白表現較低(IHC 0\/FISH+: HR 0.92; IHC1+\/FISH+: HR 1.24)的族群的療效總體提升不高，反之，HER2蛋白表現較高(IHC2+\/FISH+: HR 0.75; IHC 3+\/FISH+: HR 0.58)的族群的療效總體提升較高。"
    ],
    "does": "2243",
    "packageUnit": [
        {
            "packageSpec": "附等支數20mL小瓶稀釋液，100支以下",
            "packageUnit": "03"
        },
        {
            "packageSpec": "440毫克",
            "packageUnit": "L2"
        }
    ],
    "medMCode": "05",
    "maMedCode": "",
    "medDCode": "D",
    "mainCategory": "D",
    "drBaseId": "2F334354-1649-49E6-B25D-43C1D3339648",
    "subCategory": [],
    "ingredientsDesc": [
        "TRASTUZUMAB"
    ],
    "restraintItemsCode": [
        "02 輸 入",
        "07 新藥監視",
        "1D 須執行風險管理計畫",
        "5F 免除銜接性試驗",
        "91 生物相似性藥品"
    ],
    "applicantName": "台灣生資科技股份有限公司",
    "applicantAddr": "臺北市內湖區新湖二路158號5樓",
    "medClass": null,
    "efficacy": " ",
    "mdFormat": null,
    "productAnnotation": "",
    "mdKind": [],
    "monitorDate": "2023-12-06",
    "licidNew": null,
    "licidOld": null,
    "factoryDtoList": [
        {
            "id": "006C23B3-5011-42E4-9CE5-8AF474612C73",
            "factoryCode": "1",
            "factoryName": "BIOCON BIOLOGICS LIMITED",
            "factoryAddr": "BLOCK NO. B1, B2, B3, Q13 OF Q1, AND W20 & UNIT S18, 1ST FLOOR, BLOCK B4, SPECIAL ECONOMIC ZONE, PLOT NO. 2, 3, 4 & 5, PHASE IV, BOMMASANDRA-JIGANI LINK ROAD, BOMMASANDRA POST, BENGALURU- 560099, INDIA",
            "factoryCompanyAddr": null,
            "countryCode": "IN",
            "processCode": [
                {
                    "value": "2I",
                    "name": "原料藥及成品製造廠"
                }
            ],
            "processCodeStr": "2I;原料藥及成品製造廠",
            "factoryKind": "M",
            "factoryNo": "FIN1121100",
            "factoryInfo": null,
            "qsd": null,
            "qsdList": [],
            "factoryMadeIn": null
        }
    ],
    "ingredientsDtoList": [
        {
            "ingredientsKind": "1",
            "ingredientsCode": "1013000500",
            "ingredientsName": "TRASTUZUMAB",
            "ingredientsDesc": "TRASTUZUMAB",
            "concentDesc": "",
            "concent": "440.000000",
            "concentUnit": "001",
            "seq": "1",
            "prescription_seq": "1",
            "prescription_Kind": "1"
        }
    ],
    "authDtoList": [],
    "iomDtoList": [],
    "changeDtoList": [],
    "atcList": [
        {
            "isMain": "1",
            "atcCode": "L01FD01"
        }
    ],
    "licBaseId": "47FF0CF3-65F4-4ECE-AF14-FC0D7DF4A3E2"
}